{"id":"W3204360130","doi":"10.1136/ijgc-2021-002933","title":"ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001482302,0.0005137799,0.001764745,0.0005250311,0.00008648438,0.0001148983,0.0003187547,0.0002539032,0.002251927],"category_scores_gemma":[0.0005405405,0.0003670901,0.0004786818,0.0004644273,0.0001855802,0.0002784625,0.00003630528,0.0005762674,0.000006193588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003331222,"about_ca_system_score_gemma":0.001911658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00145116,"about_ca_topic_score_gemma":0.000984413,"domain_scores_codex":[0.9955305,0.000512786,0.001573232,0.0006599795,0.001213472,0.000510001],"domain_scores_gemma":[0.9968169,0.0008800075,0.0008646021,0.0002682364,0.0008439559,0.0003263405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9292773,0.005587657,0.004620348,0.00002072541,0.00186727,0.0013735,0.003417906,0.004824021,0.008056595,0.0008906093,0.000334525,0.03972957],"study_design_scores_gemma":[0.970534,0.005463549,0.00249875,0.0009510367,0.0002413622,0.0001754208,0.0003320869,0.005807607,0.006751525,0.0030375,0.003741344,0.0004657948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9685022,0.002222162,0.005194073,0.01995973,0.00121331,0.002210686,0.00004633345,0.00002870522,0.0006228347],"genre_scores_gemma":[0.9845138,0.002992319,0.003334199,0.006760126,0.0005861172,0.001140879,0.00003573966,0.00006538178,0.0005714903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04125674,"threshold_uncertainty_score":0.9998781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02838084312433299,"score_gpt":0.3740461018474168,"score_spread":0.3456652587230838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}